Mobile app to enhance health outcomes for advanced lung cancer patients
Randomized Trial of Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
This study is testing a mobile app called THRIVE to see if it can help people recently diagnosed with advanced lung cancer feel better and manage their symptoms compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 3 sites (Los Angeles, California and 2 other locations) |
| Trial ID | NCT06427954 on ClinicalTrials.gov |
What this trial studies
This multi-site randomized trial evaluates the THRIVE digital health application against usual care in 250 patients recently diagnosed with advanced lung cancer. Participants will be randomly assigned to either the THRIVE app group or the control group, with the app designed to improve quality of life, manage physical and psychological symptoms, and enhance coping and self-efficacy. The study will utilize iPads to facilitate app usage and will measure patient-reported outcomes at multiple time points to assess both short and long-term effects of the intervention.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with advanced non-small cell lung cancer or extensive stage small cell lung cancer within the last 12 weeks, who are able to engage with the digital app.
Not a fit: Patients with significant uncontrolled psychiatric disorders or cognitive impairments that hinder participation in study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the quality of life and psychological well-being of patients with advanced lung cancer.
How similar studies have performed: Other studies utilizing digital health interventions for cancer patients have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (greater than or equal to 18 years) * Diagnosed with advanced non-small cell lung cancer (NSCLC) that is not being treated with curative intent or extensive stage small cell lung cancer (SCLC) within the past 12 weeks. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0-2 (i.e., fully active to at least ambulatory and up and about more than 50% of waking hours). * Sufficient English proficiency to utilize THRIVE in English (Note: patients can complete outcome measures in Spanish if preferred). Exclusion Criteria: * Significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures.
Where this trial is running
Los Angeles, California and 2 other locations
- University of California Los Angeles — Los Angeles, California, United States (Recruiting)
- Veteran Affairs Greater Los Angeles Health Care — Los Angeles, California, United States (Not_yet_recruiting)
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Jennifer Temel
- Email: jtemel@partners.org
- Phone: 6177244000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.